Five new medicines recommended for approval

EMA’s human medicines committee (CHMP) recommended five medicines for approval at its April 2026 meeting.

The committee recommended granting a marketing authorisation for Cenrifki (tolebrutinib), for the treatment of non-relapsing secondary progressive multiple sclerosis, a disease of the brain and spinal cord in which inflammation destroys the protective covering around nerves and the nerves themselves.

The CHMP recommended granting a marketing authorisation for the gene therapy medicine Itvisma (onasemnogene abeparvovec), for the treatment of spinal muscular atrophy, a rare, serious inherited disease that causes weakness and wasting of the muscles.

The CHMP adopted a positive opinion for Redemplo (plozasiran) to treat adults with familial chylomicronaemia syndrome, a rare inherited disease that prevents the body from breaking down lipids (fats). This medicine provides a new treatment option for patients with a high unmet…